Skip to main content
ALPS
NASDAQ Industrial Applications And Services

Alps Group Publishes Positive Clinical Safety Data for Autologous NK Cell Therapy

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Health Tech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$0.91
Mkt Cap
$148.03M
52W Low
$0.562
52W High
$15
52W Position info
62% above low
Off High info
94% below high
Rel. Volume info
0.1× avg
Market data snapshot near publication time

ALPS sits 62% above its 52-week low of $0.562 on light trading volume (0.1× avg).

Summary

Alps Group Inc announced the publication of a peer-reviewed case study demonstrating the clinical safety and tolerability of its autologous Natural Killer (NK) cell infusions, supporting the advancement of its immunotherapy pipeline.


Key Events · Product Development and Regulatory · ALPS

  • Peer-Reviewed Publication

    Alps Group Inc announced a peer-reviewed case study in SAGE Open Medical Case Reports, detailing clinical findings for its autologous Natural Killer (NK) cell infusions.

  • Positive Clinical Data

    The study, involving nine patients, provided evidence of clinical safety and tolerability for the company's in-house developed NK cell culture protocol, with preliminary observations suggesting safety and in vitro cytotoxicity against cancer cells.

  • Patent-Pending Technology

    The publication highlights the company's patent-pending, antibody-free culture method, designed for cost-effective, large-scale production of highly pure NK cells, potentially improving accessibility to advanced immunotherapy.

  • Supports Future Clinical Trials

    These findings, combined with preclinical data, are intended to support the design of future clinical investigations in a broader patient population, advancing the company's NK cell pipeline.


Analysis · ALPS · Industrial Applications And Services

This filing is significant for Alps Group as it provides scientific validation for its proprietary autologous Natural Killer (NK) cell therapy. The peer-reviewed publication of preliminary clinical data, showing safety and tolerability in nine patients, is a crucial step in de-risking the therapy and supporting the design of future, larger clinical investigations. The patent-pending, antibody-free culture method, highlighted for its potential to enable cost-effective, large-scale production, could be a key differentiator in the competitive immunotherapy landscape. Investors should view this as a positive development that strengthens the company's biotechnology platform and its long-term potential in precision medicine.

How filings like this one have moved

In the 30 days to Nov 8, 2026, 46.9% of the 1569 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.35%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ALPS was trading at $0.91 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $148M. The 52-week trading range was $0.56 to $15.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ALPS - Latest Insights

ALPS
Oct 30, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.325
Real-time Price: $0.340 info
Change: Reverse Stock Split info
Market Cap: $54.862M info
ALPS
Oct 08, 2026, 4:22 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.3693
Real-time Price: $0.340 info
Change: Reverse Stock Split info
Market Cap: $54.862M info
ALPS
Aug 07, 2026, 4:15 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.4166
Real-time Price: $0.340 info
Change: Reverse Stock Split info
Market Cap: $54.862M info
ALPS
Aug 07, 2026, 8:00 AM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.405
Real-time Price: $0.340 info
Change: Reverse Stock Split info
Market Cap: $54.862M info
ALPS
Jun 23, 2026, 4:05 PM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $0.650
Real-time Price: $0.340 info
Change: Reverse Stock Split info
Market Cap: $54.862M info